First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia
Authors:
- Omar ValenzuelaOVOmar Valenzuela
- Sebastián IbáñezSISebastián Ibáñez
- María PoliMPMaría Poli
- Patricia RoesslerPRPatricia Roessler
- Mabel AylwinMAMabel Aylwin
- Gigia RoizenGRGigia Roizen
- Mirentxu IruretagoyenaMIMirentxu Iruretagoyena
- Vivianne AgarVAVivianne Agar
- Javiera DonosoJDJaviera Donoso
- Margarita FierroMFMargarita Fierro
- José MontesJMJosé Montes
Preprint
Abstract
Introduction/objectives: An interleukin-6 inhibition strategy could be effective in selected COVID-19 patients. The objective is to present our experience of tocilizumab use in patients with severe COVID-19. Methods: Observational retrospective cohort study. Hospitalized patients were evaluated by our multidisciplinary team for eventual use of tocilizumab. Patients with progressive ventilatory impairment and evidence of a hyperinflammatory state despite usual treatment received tocilizumab 8 mg/kg intravenous (maximum dose 800 mg), in addition to standard treatment. The use and time of use of mechanical ventilation (MV), the change of the Alveolar-arterial (A-a) gradient, of the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) and of inflammation laboratory parameters after 72 hours of tocilizumab use was evaluated. Results: 29 patients received tocilizumab. 93.1% were men, 37.9% were obese, and 34.5% had hypertension. Of the 20 patients who were not on MV when receiving tocilizumab, 11 required non-invasive MV, for an average of five days, and one of them required intubation. A-a gradient, PaO2/FiO2, and inflammation parameters improved significantly. A better lymphocyte count, which improved significantly after tocilizumab use, was significantly associated with less use of MV. Five patients presented positive culture samples after tocilizumab, three being of clinical significance. A lower lymphocyte count was associated with having a positive culture. No other significant adverse events were seen. Conclusion: Our study suggests the utility and shows the safety of tocilizumab use in COVID-19 patients who have respiratory failure and evidence of hyperinflammation. Lymphocyte improvement was a predictor of good response. Key-points: The use of tocilizumab in patients with severe COVID-19 was safe. Most of the patients presented a good response in terms of ventilatory and inflammatory parameters. Lymphocyte improvement after using tocilizumab was the main predictor of a good outcome.Keywords
All Related Versions
- Published version: Frontiers in Medicine, 7, 596916.
This publication has 25 references indexed in Scilit:
- Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patientsEBioMedicine, 2020
- Cytokine release syndrome in severe COVID-19Science, 2020
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposalThe Journal of Heart and Lung Transplantation, 2020
- COVID-19 pneumonia: ARDS or not?Critical Care, 2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- COVID-19: immunopathology and its implications for therapyNature Reviews Immunology, 2020
- Interleukin-6 in COVID-19: A Systematic Review and Meta-AnalysismedRxiv, 2020
- Coronavirus disease 2019: What we know?Journal of Medical Virology, 2020
- COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?Clinical and Experimental Rheumatology, 2020
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeThe Oncologist, 2018